Clinical and biochemical factors associated with hyperammonemia in inpatients with mental disorders treated with valproic acid: a cross-sectional analysis
Our findings highlight the potential influence of AUD and polypharmacy on the risk of hyperammonemia in subjects treated with oral VPA. Additional studies are needed to confirm these associations and to test their potential causal role in hyperammonemia. Clinical implications for limiting polypharmacy in people treated with oral VPA should be considered.
Authors
- Daniele Cavaleri (ORCID: https://orcid.org/0000-0001-5342-9394)
- Cristina Crocamo (ORCID: https://orcid.org/0000-0002-2979-2107)
- M. Morreale (ORCID: https://orcid.org/0000-0002-7061-9103)
- Ilaria Riboldi (ORCID: https://orcid.org/0000-0002-8188-800X)
- Francesco Bartoli (ORCID: https://orcid.org/0000-0003-2612-4119)
- Giuseppe Carrà
Institutions
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Therapeutic Advances in Psychopharmacology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/20451253251385730
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00